applsci-logo

Journal Browser

Journal Browser

Recent Advances in Flavonoids and Health

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: 20 July 2026 | Viewed by 1103

Editor


E-Mail Website
Guest Editor
Department of Physiology, Johann-Friedrich-Blumenbach-Institute for Zoology and Anthropology, Faculty of Biology, Georg August University Göttingen, Göttingen and Goettingen Research Campus, Göttingen, Am Türmchen 3, Gütersloh D-33332, Germany
Interests: aging; amino acids; antioxidants; inflammaging; melatonin; product development; tryptophan
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The process of development and adaptation requires safeguarding by potent antioxidant bioenergetic agents that allow for the maintaining of health by targeting and enhancing the supply of bioenergetic resources for permanent repair, recycling, and regeneration. Recent research on flavonoids demonstrates conclusively that health can be improved if neuroinflammation is successfully targeted and resolved. Future studies focusing on a research agenda that aims to target the master regulators of adaptational plasticity and developmental physiology can facilitate the progress of applied sciences and the use of such agents. Bioenergetic stimulation and trophic support result in structural and functional changes that enable appropriate responses to any kind of demand and stress. The development of flavonoids that allow for neuroprotection has to focus on the metabolic mechanisms and mediators that prevent premature aging and disease. Through your contributions to the development of applied sciences, we aim to demonstrate perspectives for the application of advanced technologies using flavonoids that have the potential to prevent and cure degenerative diseases.

Dr. Burkhard Poeggeler
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • aging degenerative diseases
  • antioxidant
  • anti-inflammatory flavonoids
  • health

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

28 pages, 2932 KB  
Review
Multitargeted Flavonoids in Glioblastoma Therapy
by María Jesús Ramírez-Expósito, Cristina Cueto-Ureña and José Manuel Martínez-Martos
Appl. Sci. 2026, 16(12), 6218; https://doi.org/10.3390/app16126218 - 19 Jun 2026
Viewed by 306
Abstract
Glioblastoma (GB) is the most aggressive primary central nervous system tumor in adults and the most common malignant primary brain tumor, representing approximately 50.9% of all malignant CNS tumors, with a median overall survival of approximately 14.6 months despite standard multimodal treatment, consisting [...] Read more.
Glioblastoma (GB) is the most aggressive primary central nervous system tumor in adults and the most common malignant primary brain tumor, representing approximately 50.9% of all malignant CNS tumors, with a median overall survival of approximately 14.6 months despite standard multimodal treatment, consisting of surgical resection, concurrent radiotherapy, and temozolomide (TMZ), followed by adjuvant TMZ (Stupp protocol). Tumor recurrence is inevitable and attributed to diffuse infiltration of neoplastic cells into the brain parenchyma, marked intratumoral heterogeneity, the presence of glioma stem cells, and the protection conferred by the BBB. Flavonoids are plant-derived polyphenolic compounds with more than 8000 identified. They have attracted growing interest as potential therapeutic agents because of their capacity to modulate multiple oncogenic signaling pathways and their favorable toxicity profile. Here we synthesize the preclinical evidence on the main flavonoids with documented activity in GB models, with emphasis on quercetin, apigenin, luteolin, and EGCG, while distinguishing glioblastoma-specific evidence from indirect findings derived from other experimental systems. We analyze their underlying molecular mechanisms, including induction of apoptosis through the intrinsic and extrinsic pathways, inhibition of cell proliferation and angiogenesis, suppression of migration and invasion, epigenetic modulation, and, particularly, the capacity to target the glioma stem cell population. We also examine the limited oral bioavailability and restricted penetration across the BBB, as these factors remain major barriers to translational development. We conclude with an analysis of emerging nanotechnological strategies, targeted delivery systems, and synergistic combinations with conventional chemotherapeutic agents, together with a cautious assessment of the current clinical evidence, which remains insufficient to support the use of flavonoids outside controlled clinical trials. Full article
(This article belongs to the Special Issue Recent Advances in Flavonoids and Health)
Show Figures

Figure 1

Back to TopTop